Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio, 6-K call announcement stay in one workspace.
Earnings call · FY2026 Q3
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio, 6-K call announcement stay in one workspace.
Research coverage
3 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Good morning, and thank you for standing by.
All participants are currently in listen-only mode. Following management's prepared remarks, we will open the call for question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference call over to Sarah Velling. Please go ahead.
Before we begin, I will take a moment to read the forward-looking statements disclaimer. This call and the question and answer session that follows contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates, and similar expressions are intended to identify forward-looking statements. These statements include, among other things, the company's expectations regarding continued revenue growth, commercial expansion, position adoption and utilization of ProTent, expansion of its U.S. commercial organization and international presence, Investing in a company's commercial, clinical, and organizational capabilities, the progress and potential impact of the choice post-marketing study, future clinical evidence generation, intellectual property protection, and the company's long-term market opportunity. Forward-looking statements are subject to risks and uncertainties, many of which are beyond the company's control. These risks are described in greater detail in the risk factor section of the company's annual report on Form 20F for the year ended December 31, 2020 files, filed with the SEC on March 17, 2026, and in other documents filed with or furnished to the SEC. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. This conference call contains time-sensitive information and speaks only as of today's live broadcast, November 18, 2026. I will now turn the call over to IceCure Medical's CEO, Ayal Shamir. Ayal, please go ahead.
Thank you, operator, and thank you, everyone, for joining us today. The first nine months of 2026 demonstrated continued commercial momentum for process, particularly in the United States, our primary commercial market. Total revenue increased 26% year over year, while U.S. sales increased 83%, reflecting the continued expansion of our commercial activities and growing adoption of process. During the third quarter, we also continue to expand our U.S. commercial presence, advance the choice post-marketing study, and strengthen the clinical evidence supporting prior ablation. We believe this development demonstrates the progress we are making in translating the clinical and regulatory foundation we have built over the past several years into commercial growth and broader physician adoption. Let me start with our financial and commercial performance in the United States. By the end of the third quarter of 2026, we nearly doubled our U.S. commercial footprint, growing from 11 states to the end of the second quarter of 2025 to 21 states. We added dedicated sales and marketing professionals in key regions, including New York, Southern California, the Midwest, and Florida, as well as additional clinical support personnel. This expansion commercial infrastructure enables us to engage with small physicians and medical institutions, provide clinical support and training, and support the adoption of your utilization of process. We believe the combination of broadened geographic coverage, the expanded commercial team, and increased physician engagement provides a stronger foundation for our continued U.S. commercial growth. Another important area of progress is our Choice Post-Marketing Study, which we designed to generate additional clinical evidence while expanding physician experience with process. Since initiating the study, we have new established three clinical sites, including West Cancer Center in Germantown, Tennessee, Advanced Health Glendon in Glendon, California, and Legacy Health in Portland, Oregon, and have begun enrolling and treating patients at participating U.S. centers. We progress from activating our first clinical site. To enrolling and treating the first patients at West Clinic Center in Tennessee, and have since announced initial patients enrolled at two participating U.S. clinical sites. We are also engaging with additional leading medical centers regarding potential participation in the study. We view choice as closely connected to our broader commercial strategy. And additional leading institutions and physicians gain clinical experience in this process, the study can generate real-world evidence, support physician confidence, and contribute to a broader adoption over time. Beyond our commercial and clinical progress in the United States, we continue to expand the regulatory and commercial footprint of procents internationally. Recent development includes regulatory approval in China and an inclusive distribution agreement in the Netherlands, further expanding the market in which procents can be commercialized. We're also seeing continued interest in physician and medical institutions in Europe, South America, and other international markets as we work to build a regulatory and commercial relationship unit to support broader adoptions of process. At the same time, we continue to thank the Scientific Foundation supporting cryoablation. During the third quarter, we highlighted two additional peer-reviewed scientific publications addressing the role of cryoablation in breast cancer treating, de-escalation, including research relating to early-stage breast cancer and axillary lymph node metastasis. We believe the continued generation of independent scientific evidence can further support physician awareness and confidence in cryoablation and continue to grow their adoption over time. In parallel, we continue to strengthen our intellectual property portfolio as processes expand into additional markets and gain broader commercial exposure. We consider our IP an important strategic asset and remain focused on protecting the technology's underlying process as we pursue broader commercial adoption globally. Taking together this development reflects the progress we are making across our commercial, clinical, and international activities. Our focus remains executing, expanding our commercial presence, increasing physician adoption and utilization of persons, advancing our clinical program, and building the evidence needed to support broader adoption. While we are still in ending stage of realizing the commercial opportunity for persons, we believe that progress we are seeing, particularly in the United States, provides a stronger foundation for continuing growth. With that, I will turn the call over to our Chief Financial Officer, Mayor Peneg, who will review our financial results in greater details.
Thank you, Rial, and good morning, everyone. I will briefly review our financial results for the nine-month ended September 30, 2026. Total revenues for the first nine months of 2026 increased approximately 26% to $2.6 million, compared to $2.1 million in the corresponding period of 2025. Gross profit increased approximately 22% to $762,000, compared to $626,000 in the final year period. As I mentioned, we are particularly pleased with the growth in the United States, where sales increased 83% year-over-year during the first nine months of the year. This performance reflects the continued expansion of our commercial activities and the growing market presence of process. Regarding operating expenses, asset and development expenses were approximately $6.5 million compared to $5.1 million in the corresponding period last year. The increase primarily reflects higher expenses related to the Choice Post-Marketing Study and other clinical and development activities. Sales and marketing expenses increased approximately 20% to $3.6 million compared to $3 million in the prior year period, primarily reflecting the continued expansion of our U.S. commercial activities, while U.S. sales were 83% over the same period. General and business sales expenses were approximately $3.5 million compared to $3.3 million in the corresponding period of 2025. Operating loss for the first nine months of 2026 was approximately $12.9 million compared to $10.8 million in the prior year period. Net loss was approximately $12.9 million compared to $10.8 billion during the first nine months of 2025. As of September 30, 2026, Cash and cash equivalents totaled approximately $8.2 million compared to approximately $8.9 million at the year-end 2025. We continue to carefully manage our financial resources while investing in the commercial, clinical, and organizational capabilities that we believe are essential to supporting our long-term growth strategy. Our investment in expanding the US commercial organization and advancing the choice study reflects our commitment to building the infrastructure and clinical evidence needed to support broader adoption of process. With that, I will turn the call back to the operator to open the line to questions.
Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. If you have a question, please press star 1. If you wish to cancel your request, please press star 2. If you are using speaker equipment, kindly leave the answer before pressing the numbers. Your questions will be pulled in the order they are received. Please stand by while we pull for your questions.
The first question is from Scott Henry of AGP. Please go ahead.
Thank you, and good morning or afternoon, depending on location. Starting on the revenue side, last year we saw a significant sequential boost in Q4 of the year. Do you think we'll see that this year, or is that kind of a one-time event? Thank you.
It's got mail. Please answer that, and if needed, Shad will add to it.
I think maybe Shad will start, and I will add some color for the rest of the world. Shad, please go ahead.
Yeah, thanks for the question. I can speak specifically to the United States. You know, we feel like we're starting to get some real traction here in the U.S. and also getting some momentum with that. We would expect that our sales revenue would continue to increase quarter over quarter. Mayor, do you want to talk about the rest of the world?
Yeah, I think we showed, and it's also seen in the square that we have some kind of seasonality. You know, revenue, while Q3 is mostly weaker than the others, together with Q1, Q4 is normally our best. I cannot say it will be the same, it will be the best, the same as last year, maybe even better, but it will be better, we assume, of course, a project is better than Q3 206.
Okay, great. Thank you for that feedback. And then, you know, without giving guidance on 2027, can you talk about your expectations, how the revenue ramp should continue? It sounds like things are picking up and we should see accelerating revenue growth in 2027, but I just wanted to get your thoughts on it. Thank you.
So, again, we're not giving guidance, and thank you for the question. It's a good one. We do see acceleration in sales and the projection for next year for revenue is a healthy double-digit growth. I would say that in this way.
Okay, great. And then if I could just get one final question. On the choice study, are you getting, you know, what kind of early feedback are you getting? Are the physicians finding it easy to move up the learning curve? Just any kind of feedback you're getting from the early days. Thank you.
Hi Scott, this is Eyal. I will answer that and if needed, Shad and our VP sales for North America and Shai, our COO, will be able to add. So as we announced the first two sites, one of them is running by Dr. Richard Fine together with some of his colleagues and West Clinic and Dr. Fine, they have very well experienced. They were participated to the I3 study and they did other cases. Same for Glendale, California, Dr. Dennis Holmes. He is a long user, high-volume user, so they are both experienced. And one of the new sites that we announced by Dr. Natalie Johnson from Seattle, Oregon, past president of the society, she is a new user, and she did some cases before at the PMS, and she did the first case for the PMS. So she found it for the patients and for the users, very easy to use, excellent minimally invasive solutions, so extremely satisfied with the cases that she did.
Okay, great. Thank you for taking the questions.
Thank you.
The next question is from Kemp Dolliver from Brookline Capital Markets. Please go ahead.
Great. Thank you. So, what's the installed base of consoles in the U.S. now?
But as you could see, you know, from the revenue growth, and as we announced, you know, also new sites, again, we are not giving guidance. Last time that we discussed the active site, you know, was on June. We are still having, you know, some orders that we need to ship. to ship some orders before the end of the year. So I believe that in a few weeks or months or two, we will give some update information of that, but we definitely see a growth in cells and sites.
Okay, good. And, you know, to clarify on the CHOICE study, are you currently at five sites?
Yeah. Shad, could you take these questions?
Yes, we're currently at four sites as of today, but we're expecting to finalize some additional sites here in the very near future. So we've made some really good progress since the last call in regards to the recruiting process of sites, the contracting with the sites, and also kind of the commercial aspect as well. So I think you should kind of expect to see kind of more of a steady cadence of new sites being enrolled into the study over the next couple of months.
Okay, great. And the last question is, the commercial team, is it, you know, I think a month or so ago it was around seven, and you were thinking it would be nine at the end of the year. Is that still your plan? So, Kemp, as you saw in the earnings release from this morning, recently, actually almost a week ago, we joined an excellent expert to support us, you know, in Florida, extremely important market. Two to three months ago, we had someone in California. Again, excellent and very important market for future growth. We might add another one until the end of the year or very early next year. And next year, we are planning, of course, to grow with the team in order to support the sales growth, as the mayor mentioned, with important double-digit growth in the U.S. Great. Thank you.
Thank you, Kim. Thank you.
The next question is from Thomas McGovern from Maxim Group. Please go ahead.
Hey, guys. Thanks for taking my question. The first one's just on the choice study. Following the second quarter update, we were anticipating the first patient to be enrolled in September, and, you know, we saw the update that they were treated back in October. Just curious, you know, where's that pipeline now, and how do you think, how do you, what's your outlook compared to those deadlines that we've discussed in the past? We were expecting 80 patients by the end of March 27, and then the 400 by March 2029. Are those deadlines that you believe you're on track to hit?
You know, I'm not sure that we will be able to do the 400 within the three years because, you know, some of the contracts, you know, agreement, some of the sites is taking them longer time. Early this year, you know, we had some difficulties, you know, to travel, but we are joining, you know, more and more sites that they have, you know, pipeline of patients. Some of them even will join and start to treat patients before the end of the year and very early next year. But I believe that we will be able to fill the gap one more site will be on board. And I know that some of them are having even patients that really fit to the trial and waiting to be treated. But at the moment, it'd be too early to say that if we will be able to meet the 400 exactly three years, or maybe some short time after that, or whatever.
Okay, and you guys have some flexibility to go to the FDA and kind of articulate that case and get some extension time there?
Sure, we have continuous communication with the FDA. We are giving them also updates, so we, of course, we will discuss it with them in a mutual way. We would like to see the patients, and they like to see the patients, so I'm sure that we will come to a mutual agreement on that.
Okay, great to hear. All right, and then on the international side of the business, you guys gave updates on the approvals for both regulatory and IP approvals in China and the Netherlands distributor. I'm just curious, you know, how do you guys plan to go to market in China? Are you guys expecting to do a partnership, you know, have a distributor relationship? And when can we start to see that revenue come in? And then the follow-up questions would be on Japan and Canada. Just curious if we can get an update on timelines for approval on that front.
Yeah. Okay, so I will start with China. We are now in discussions with some potential partners, mainly more as a mode of distribution. In China, of course, you need to work with them, you know, in a close partnership, but it will be more like a distribution. So, as soon as we have something in place, we will do a proper announcement as needed. So, we are working on that. Health Canada, we are waiting on the breast cancer Canada Health approval, as it could be in the next few weeks, maybe to take, you know, two to four months. We expect we answer them all the questions that they had. And we're expecting to get the approval in the next few months. And Japan, we expect that Toromo will make the submission to the Japanese FDA, to the PMDA, during the first semester of 27.
Understood. I appreciate you answering all my questions.
Thank you.
If there are any additional questions, please press star 1. There are no further questions at this time. I will turn the call over to Eyal Shamir for concluding remarks, please.
Thank you, everyone, for questions and for joining us today. As we look ahead, our priorities are clear. Accelerating U.S. commercial growth, expand physician adoptions and utilization of persons, advance the choice study, and continue building the clinical evidence supporting prior ablation. With U.S. sales up to 83 year over year, during the first nine months of 2026, an extended commercial footprint. And continuous clinical progress. We believe we are building a stronger foundation for the next phase of process commercialization. We remain focused on execution and on translating this progress into broader adoptions and long-term value for our shareholders. Thank you again for your continuous interest and support. We look forward to updating you on our progress.
This concludes the IceCure Medical Third Quarter and Nine Months 2026 Financial Results Conference Call. Thank you for your participation. You may go ahead and disconnect.
10:30 to 23:51 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Thank you, and good morning or afternoon, depending on location. Starting on the revenue side, last year we saw a significant sequential boost in Q4 of the year. Do you think we'll see that this year, or is that kind of a one-time event? Thank you.
Eyal Shamir: It's got mail. Please answer that, and if needed, Shad will add to it.
Also speaking: Mayor Peneg, Speaker 0
Great. Thank you. So, what's the installed base of consoles in the U.S. now?
Eyal Shamir: But as you could see, you know, from the revenue growth, and as we announced, you know, also new sites, again, we are not giving guidance. Last time that we discussed the active site, you know, was on June. We are still having, you know, some orders that we…
Also speaking: Speaker 0
Hey, guys. Thanks for taking my question. The first one's just on the choice study. Following the second quarter update, we were anticipating the first patient to be enrolled in September, and, you know, we saw the update that they were treated back in October. Just curious, you know, where's that pipeline now, and how…
Eyal Shamir: You know, I'm not sure that we will be able to do the 400 within the three years because, you know, some of the contracts, you know, agreement, some of the sites is taking them longer time. Early this year, you know, we had some difficulties, you know, to…
SEC call announcement
Filed Nov 18, 2026 · complete as-filed document